5 recruiting, 1 completed, 1 withdrawn. 6 Phase 2, 5 Phase 1, 2 Phase 3.
By phase and status
Follow Cabaletta Bio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | | 2026-06-01 | 2026-06-25 |
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
CABA-201 - Generalized Myasthenia Gravis (gMG) | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 24 | 2024-12-17 | 2026-10-19 |
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
CABA-201 - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Recruiting | Cabaletta Bio | 37 | 2024-07-02 | 2026-10-16 |
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
CABA-201 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 28 | 2024-02-16 | 2026-10-06 |
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
CABA-201 following preconditioning with fludarabine and cyclophosphamide - Idiopathic Inflammatory Myopathy, Dermatomyositis | Phase 2 / Phase 3 | Recruiting | Cabaletta Bio | 74 | 2023-12-20 | 2026-10-15 |
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
MuSK-CAART - MuSK Myasthenia Gravis | Phase 1 | Completed | Cabaletta Bio | 7 | 2022-11-23 | 2025-11-10 |
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
DSG3-CAART, CABA-201 - Pemphigus Vulgaris | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 40 | 2020-09-29 | 2026-10-15 |
Conditions studied
Autoimmune Diseases (7) · Immune System Diseases (2) · Myasthenia Gravis (2) · Dermatomyositis (1) · Lung Diseases, Interstitial (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Muscle Weakness (1) · Musculoskeletal Diseases (1) · Myositis (1) · Neuromuscular Diseases (1) · Pemphigus (1)
Interventions
Cyclophosphamide (1) · fludarabine (1)
Countries
United States (6) · Canada (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1)
Results publications
PMID 38608709, PMID 39245937, PMID 42201777